Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs

被引:497
作者
Shen, Xiulong
Corey, David R. [1 ]
机构
[1] Univ Texas Southwestern Med Ctr Dallas, Dept Pharmacol, 6001 Forest Pk Rd, Dallas, TX 75390 USA
基金
美国国家卫生研究院;
关键词
DUCHENNE MUSCULAR-DYSTROPHY; DENSITY-LIPOPROTEIN CHOLESTEROL; TELOMERASE INHIBITOR IMETELSTAT; ALLELE-SELECTIVE INHIBITION; MUTANT HUNTINGTIN; SILENCING COMPLEX; APOLIPOPROTEIN-B; IN-VITRO; SIRNA; REDUCTION;
D O I
10.1093/nar/gkx1239
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
RNA plays a central role in the expression of all genes. Because any sequence within RNA can be recognized by complementary base pairing, synthetic oligonucleotides and oligonucleotide mimics offer a general strategy for controlling processes that affect disease. The two primary antisense approaches for regulating expression through recognition of cellular RNAs are single-stranded antisense oligonucleotides and duplex RNAs. This review will discuss the chemical modifications and molecular mechanisms that make synthetic nucleic acid drugs possible. Lessons learned from recent clinical trials will be summarized. Ongoing clinical trials are likely to decisively test the adequacy of our current generation of antisense nucleic acid technologies and highlight areas where more basic research is needed.
引用
收藏
页码:1584 / 1600
页数:17
相关论文
共 141 条
[1]   FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides [J].
Aartsma-Rus, Annemieke .
NUCLEIC ACID THERAPEUTICS, 2017, 27 (02) :67-69
[2]   FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga [J].
Aartsma-Rus, Annemieke ;
Krieg, Arthur M. .
NUCLEIC ACID THERAPEUTICS, 2017, 27 (01) :1-+
[3]   Theoretic Applicability of Antisense-Mediated Exon Skipping for Duchenne Muscular Dystrophy Mutations [J].
Aartsma-Rus, Annemieke ;
Fokkema, Ivo ;
Verschuuren, Jan ;
Ginjaar, Leke ;
van Deutekom, Judith ;
van Ommen, Gert-Jan ;
den Dunnen, Johan T. .
HUMAN MUTATION, 2009, 30 (03) :293-299
[4]   Frontiers and Approaches to Chemical Synthesis of Oligodeoxyribonucleotides [J].
Abramova, Tatyana .
MOLECULES, 2013, 18 (01) :1063-1075
[5]   Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides [J].
Ackermann, Elizabeth J. ;
Guo, Shuling ;
Benson, Merrill D. ;
Booten, Sheri ;
Freier, Sue ;
Hughes, Steven G. ;
Kim, Tae-Won ;
Kwoh, T. Jesse ;
Matson, John ;
Norris, Dan ;
Yu, Rosie ;
Watt, Andy ;
Monia, Brett P. .
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2016, 23 (03) :148-157
[6]   Deciphering Seed Sequence Based Off-Target Effects in a Large-Scale RNAi Reporter Screen for E-Cadherin Expression [J].
Adams, Robert ;
Nicke, Barbara ;
Pohlenz, Hans-Dieter ;
Sohler, Florian .
PLOS ONE, 2015, 10 (09)
[7]   Gene profiling study of G3139- and Bcl-2-targeting siRNAs identifies a unique G3139 molecular signature [J].
Anderson, EM ;
Miller, P ;
Ilsley, D ;
Marshall, W ;
Khvorova, A ;
Stein, CA ;
Benimetskaya, L .
CANCER GENE THERAPY, 2006, 13 (04) :406-414
[8]  
[Anonymous], 2003, NAT CELL BIOL, V5, P489
[9]   Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia [J].
Baerlocher, Gabriela M. ;
Leibundgut, Elisabeth Oppliger ;
Ottmann, Oliver G. ;
Spitzer, Gary ;
Odenike, Olatoyosi ;
McDevitt, Michael A. ;
Roth, Alexander ;
Daskalakis, Michael ;
Burington, Bart ;
Stuart, Monic ;
Snyder, David S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (10) :920-928
[10]   Relative Bcl-2 independence of drug-induced cytotoxicity and resistance in 518A2 melanoma cells [J].
Benimetskaya, L ;
Lai, JC ;
Khvorova, A ;
Wu, SJ ;
Hua, E ;
Miller, P ;
Zhang, LM ;
Stein, CA .
CLINICAL CANCER RESEARCH, 2004, 10 (24) :8371-8379